

SCREENING IN LOW RESOURCE SETTING

Dr. UMA K. Deví

Dept of Gynaec-Oncology

Kídwaí Memoríal Instítute of Oncology

BANGALORE

Karnataka , Indía



Cervical cancer continues to be a major burden in most developing countries



493,000 new cases 1.4 million prevalent cases 273,000 deaths

More than 80% of world burden

📕 < 3.9 📕 < 7.4 📒 < 11.3 📕 < 16.8 📕 < 53.5

Magnitude of **CERVICAL CANCER**

- Worldwide per year **500,000** new cases (15 % of all female cancers) estimated, (>**50%** die)
- 83 % (**415,000** cases) occur in developing countries
- India alone contribute one fifth (132,000 cases) of total burden in the world
- One in 45 women had the probability of developing cervical cancer (0 74 years)

NATIONAL CANCER REGISTRY PROGRAMME

(Indian Council of Medical Research)



LEADING **SITES** OF **CANCERS : FEMALES** Pooled AARs/100,000 in **INDIA**

SITE	AAR
BREAST	25.1
CERVIX	21.2
OVARY	6.7
ORAL CAVITY	6.4
OESOPHAGUS	5.5
STOMACH	3.4
GALL BLADDER	3.2
LEUKAEMIA	2.9
LUNG	2.7
CORPUS UTERI	2.5

Cancer of the Cervix Uteri

- Cervical cancer is the second leading site of cancer among women in all the Indian registries except at Chennai and Barshi where it is the first leading site.
- In India approximately 1 out of 27 to 104 women are at a chance to develop cervix cancer during their life time
- The incidence of cervix cancer begins to rise in the late twenties.
- Estimated number of new cervical cancers in 2007 in India 132,000.







CERVICAL CANCER BURDEN

- Annually 132,000 new cases of cervical cancer register in PBCR
- 75,000 women die of Cx
 CA per year in India
- > 80 % require diagnostic & treatment facilities

- 84 % occur between the age of 35-64 yrs
- 20% default after the diagnosis at RCC
- 30% non-complaint to complete treatment
- 50% complete trt &
 < 30 % complaint for
 F.U.

Inequities:

Developed countries	Developing countries		
Incidence and mortality rate declined in the past 40 yrs.	Incidence and mortality continues as an enormous problem		
Accounts for 3.6% of new cases, cumulative risk of 0.8%	Accounts for 15% of new cases, cumulative risk of 1.5%		
Screening services for 80% of population.	Screening services used by 5% of population.		
Successfully organized cytology based screening	No organized screening programmes available.		

Key Barriers to Cervical Cancer Prevention

- Early Detection Services Unavailable, Unreliable
- Treatment of Precancer
 - Inaccessible
 - Inappropriate
 - Inadequate follow up of women needing treatment
- Lack of monitoring & evaluation for timely corrective action & improving program performance
- Failure to reach target age group
- Limited awareness of cervical cancer as a health care problem, lack of a policy, lack of political will

Magnitude of Cervical Cancer:Low Resource Countries

- UNDIAGNOSED & UNNOTICED DEATHS due to Cervical Cancer is a concern to the civilized Nation
- Responsibility to identify these needy women



Importance of Cervical Cancer Control in INDIA

- Emergence is need of :
- Health education,
- Trained health care providers ,
- Cytotechnicians,
- Committed resource personnel & expertee
- Gynaec / Oncology team
- Gynaec Onco -Pathology
- Gynaec preventive Oncology
- Social & community medicine , policy makers



Role of Professional Organizations

- AGOI
- FOGSI
- IGCS
- ASGO
- ISO
- AROI
- IAPMO
- IAPCC
- NGO





Screening options available:

- **1.** Conventional cytology
- 2. Alternative approaches:

-- VIA

- -- VILI
- -- VIAM
- -- HPV DNA testing
- 3. New experimental methods:
 - -- Polar probe
 - -- Molecular biomarkers(E6/E7 mRNA exp,p16 exp)
 - -- Microarray analysis.

EARLY DETECTION : CA CX??

PAP TEST HPV TEST

VI/ VIA / VILI

CERVICOGRA PHY

COLPOSCOPY

TRUE SCAN

VISUAL INSPECTION TECHNIQUES

 VI : By HW / ANM : Down staging Cx Ca

• VIA:

Sensitivity : 66-96% Specificity : 64-98% [Obs /Gyn Surv 2003;58(8):543-50]

*Detection of CIN 2/3 using VIA ,VILI & PAP of ASCUS / LSIL : 3.7 ,3.3,4.5 & 4.2 / 1000 WOMEN . [Int J Gyn obs .2009;105(2):145-9]



RCTI in a low resource setting in Rural India

- Single round cytologic testing or VIA : not associated with reduction in advanced Cervical Cancer.
- The age std rate of invasive cancer among screen negative women was almost four times less in HPV -ve women compared to cytologic &VIA -ve women, indicating that -ve HPV test had a high NPPV.

[N Engl J Med 2009 ; 360: 1385 -94]

Screen & Treat modality ???

 By VI & Cryotherapy at the same sitting : effectively cured CIN in 88% women , including baseline diagnosis of CIN 3 .

(Int J Gyn Obs 2008;101(2):172 - 7)

• ?? Safety , Acceptability & feasibility

[Am J Obs Gyn 2007 ; 196 (4) : 407]

 A Randomized trial in South India found a 25% reduction in Cervical -Cancer incidence & 35% reduction in mortality compared to controls with VIA followed by Cryotherapy. (Lancet 2007 : 370:398-406)

Screen & Treat modality ???

- By PAP & HPV test ;
- Overcome the problem of loss to F.U. but still present the problem of infrastructure & cost
- ? Women over 40 years screen at 5 yr

- Ideal situation in high resource setting :
- HPV DNA testing : 20-40 % high sensitivity but 5-10% lower specificity than PAP.
- [J Natl Cancer Inst Monogr 2003 ; 31:89-96]
 - The -ve predictive value by PAP & high - risk HPV DNA -ve is extremely high , over 99.9 % in most studies .

Development strategy for Early detection of Cervical Cancer Involvement of family / men. Panchayat raj personnel. Primary health care providers. District hospital staffs. Medical college colleagues Non-governmental organisation. Regional cancer institutions. Policy makers

Resources for Cervical Cancer Control-India

- Twenty seven regional cancer centres.
- Total 304 Medical colleges
- Government medical colleges
- Private medical colleges
- District hospitals
- Primary health care units
- Public & private Organization

Cervical Cancer Screening Programme

- Organised or Opportunistic.
- Selective or General
- Single or Multiple phase.
- $\downarrow \downarrow$ of incidence.
- $\downarrow \downarrow$ of mortality.
- $\downarrow \downarrow$ of cost.

Cervical Cancer – A PUBLIC HEALTH PROBLEM

"The focus of cancer must shift from PALLIATION TO CURATIVE and from CURATIVE TO PREVENTION "



AGOI Proposal.....Gynaecologist <u>PAP TEST</u> IIIIV V

ASYMP Rx inf **Ref colpo clinic**

AnnualRpt pap3-5 /10yrs papafter 6/12m

Colpo Clinic

Satisfactory

Unsatisfactory

Abnormal Normal Abnormal

Colpo Bx Reg F/U Colpo Bx+ECC

↓ N CIN I/II CIN III CIN I/II N FU cryo CB/ CB cryo / TAH LEETZ LASER LEETZ TAH FU

STRATEGIES FOR CERVICAL CANCER

- Simple
- Cost effective
- Minimally reliant upon infrastructure
- Easy to learn
- Easy to train health care providers
- Results should be available immediately
- Integrated into "Screen & Treat "strategy

CERVICAL CANCER SCREENING & DETECTION OF CIN(Jan 2000 - 03)

	HPV test	Pap test	VIA
Eligible	34, 126	32,058	34,074
Evaluable (Screened)	27,192 (79.7 %)	25,549 (79.7 %)	26,765
Positive	2,812 (10.3 %)	1,787 (7.0 %)	3,733 (13.9 %)
Colposcopy	2,505 (89.1 %)	1,507 (87.9 %)	3,684 (98.7)
CIN1	603 (2.2 %)	486 (1.9 %)	1,429 (5.3 %)
CIN 2,3	245 (0.9 %)	26 (1.0 %)	195 (0.7 %)
Cancer	73 (0.3 %)	83 (0.3 %)	82 (0.3 %)

Cx Ca. Incidence and Mortality

[The NEJM – Apr 2, 2009, No14, Vol 360 : 1385-1394]

	HPV test	Pap Test	VIA	Control
Stage I	60 %	60 %	60 %	28 %
Death	34	54	56	64

Barriers to Implementation

- Community & Individual barriers :
 - * Cx Ca Public health problem
 - * Lack of KAP about Cx Ca
- Medical barriers :
 - * VIA : operator dependent with high inter-observer variation
 - * Requiring proper quality control & training assessment protocol
 - * Frequent retraining health care providers
 - * Unnecessary treatment of normal women in single visit approach
 - * High ref rate for further evaluation

VIA:

- No uniform criteria for reporting VIA positivity
- No permanent record system for VIA
- Not suitable for postmenopasual women where SCJ receded

Barriers to Implementation

- See & Treat :
 - * Not suitable for women with HG lesion
 - * Not suitable for endocx lesions
 - * Not suitable for vag Fx /large/extension
 - * Not suitable for atrophic cervix
- * Maintenance of cryotherapy equipment Single time HPV test : Cost & lab facility

Barriers to Implementation

- Technical & Organizational barriers
- Political barriers
 - * Lack of priority for women reproductive health
 - * Lack of national policies & appropriate guidelines

IIGO Program Joint Collaborations in 2005.....

- IIGO program :
- Gyn prevent Oncol
- Gyn Surg oncology
- Gyn Medl & Rad Onc
- Gyn-Onco-pathology
- Gynaec Onco Nurse Training
- Gyn -Onco Registry



Role of Gynaecologist: Cervical Cancer Control

- Appropriate screening test.
- Early detection
- Treatment of preinvasive lesion
- Clinical staging/ early reference
- Appropriate selection of patients for surgery
- Identification & reference of poor prognostic patients
- Adequate management.

AGOI PROPOSAL : CA.CX : CURE AND CARE

- Fund raising for PREVENTABLE, & CURABLE CANCERS.
- To establish palliative / Hospice care.
- To improve QOL.
- To develop IIGO & Breast Ca Care foundation , Research & training centre

CHALLENGES : CA.CX



VISION HARMONY CO-PERATION CO-ORDINATION INTEGRITY UNITY AGOICON - November, 12th -14th, 2010 - B'lore IGCS Regional workshop, April 2-3rd INDIA





The13th Biennial Meeting, International Gynecologic Cancer Society (IGCS)



Save the Date

Prague, Czech Republic, European Union October 23-26, 2010

www.kenes.com/igcs

THANK YOU

